Pay attention to subsequent arterial ischemic events after intracerebral hemorrhage / 中华神经科杂志

Survivors of intracerebral hemorrhage (ICH) have significantly higher risks of both arterial ischemic events and recurrent ICH after the first event. This uncertainty leaves clinicians with dilemmas about the therapy strategies for the secondary prevention of major vascular events after ICH. Clinicians mainly focus on the prevention of hemorrhage recurrence but overlook the increased risk of ischemic disease after ICH in routine clinical practice. Secondary stroke prevention measures after ICH including antithrombotic and statin treatments remain challenging due to the lack of dedicated studies with strong evidence. Decision-making on stroke prevention requires algorithmic approaches based on the hemorrhagic and ischemic risk stratification. This article systematically reviews the current evidence for the prevention and management of subsequent arterial ischemic events after ICH, aiming to promote further attention and research to address the current controversies and knowledge gap on this topic.

Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI / 中国临床药理学与治疗学

AIM: To observe the clinical efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). METHODS: A total of 172 patients with ACS who had undergone PCI from October 2018 to April 2022 in our hospital and Subei People's Hospital of Jiangsu Province were selected and divided into three groups according to the patients' medication status: 50 patients in group A (tegretol alone group); 62 patients in group B (aspirin enteric coated tablets + tegretol group); and 60 patients in group C (aspirin enteric coated tablets + clopidogrel hydrogen sulfate group). The patients were observed for postoperative recurrent angina pectoris, in-stent restenosis, revascularization, heart failure, and bleeding. RESULTS: There were no significant differences in postoperative recurrent angina, in-stent restenosis, re-hematologic reconstruction, heart failure, and bleeding between the 3 groups. CONCLUSION: There is no increase in ischemic events, heart failure in patients treated with tegretol antiplatelet therapy alone after a short course of dual antibiotics after PCI and it reduces risk of bleeding.

Influence of different doses of atorvastatin on the blood lipids and cardiac ischemic events after percutaneous coronary intervention in patients with coronary heart disease / 中国基层医药

Objective To observe the influence of different doses of atorvastatin on the hyperlipidemia and cardiac ischemic events after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD).Methods 132 cases with CHD in our hospital were randomly divided into group A,group B and group C,and they were given different doses of atorvastatin after the PCI surgery,.The changes of lipid levels and cardiac ischemic events were compared.Results TC,TG and LDL-C levels in the three groups were significantly decreased after treatment,and the HDL-C level significantly increased (P ＜ 0.05),TC and LDL-C of group B and group C were significantly lower(P ＜ 0.05).The cardiac ischemic events and the incidence rate of a variety of adverse reactions of group C were less than group A and group B,but the differences were not significant (P ＞ 0.05).Conclusion Highdose atorvastatin (40mg) can effectively decrease blood lipid levels in CHD patients after PCI,reduce the incidence rate of cardiac ischemic events,and it is safe,effective,which is worth to be promoted and applicated in clinical.

Effect of blood pressure control at different time on prognosis of stroke patients / 第三军医大学学报

Objective To observe the effect of antihypertension treatment at different time after acute onset of stroke on patients' prognosis.Methods Ninety-six patients with ischemic stroke were randomly divided into three groups who received antihypertension treatment separately at the 4th,7th and 10th day after onset.Patients' neurologic deficit and ischemic events were observed at 1 month and 3 months in follow-up.Results Patients who received antihypertension at the 4th day after onset had severer neurologic deficit and more ischemic events than those who received antihypertension at the 7th or 10th day.The patients who received antihypertension treatment at the 7th and 10th day did not show significant difference in prognosis and occurrence rate of ischemic event.Conclusion It is preferable to start antihypertension treatment at the 7th day after onset for patients with ischemic stroke.